14 research outputs found
Individual renal function biomarkers of the dogs under study before (at day 0) and after (at day 28) treatment with marbofloxacin.
<p>Individual renal function biomarkers of the dogs under study before (at day 0) and after (at day 28) treatment with marbofloxacin.</p
Blood pressure measurement on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the dogs under study.
<p>Values are expressed as the mean±standard deviation. <sup>a</sup><i>p</i><0.02 vs day 0, <sup>b</sup><i>p</i><0.02 vs day 7.</p
Haematological and biochemical parameters of 28 dogs with leishmaniasis and CKD before (at day 0) and after treatment (at day 28).
<p>Haematological and biochemical parameters of 28 dogs with leishmaniasis and CKD before (at day 0) and after treatment (at day 28).</p
Individual clinical score, antibody titers and parasitic load of the dogs under study before (at day 0) and after (at day 28) treatment with marbofloxacin.
<p>Individual clinical score, antibody titers and parasitic load of the dogs under study before (at day 0) and after (at day 28) treatment with marbofloxacin.</p
Concentrations of plasma creatinine (A), plasma urea (B) and urine protein to creatinine (UPC) ratio (C) on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the dogs under study.
<p>Values are expressed as the mean±standard deviation.</p
Principal components analysis plot.
<p><b>Interrelation between the main parameters studied at day 0 (A) and at day 28 (B)</b>. Alb: albumin; AbTiter: antibody titer; Crea: creatinine; CScore: clinical score; DBP: diastolic blood pressure; Glob: globulins; P: phosphate; ParLoad: parasitic load; PCV: packed cell volume; SBP: systolic blood pressure; UCystatin: urine cystatin C; UFerritin: urine ferritin; UPC: urine protein to creatinine ratio.</p
Inhibition of TRPM7 abrogates protective effect of magnesium on calcification and gene expression on VSMC.
<p>VSMC were cultured with 3.3+1.4 mM Mg with the TRPM7 inhibitor 2-APB (10 µM). VSMC with 3.3 mM P+0.8 mM Mg were also included. The graphics are <b>(A)</b> calcium content, and the relative mRNA expression of <b>(B)</b> Cbfa-1, <b>(C)</b> MGP, and <b>(D)</b> OPG. <b>a</b>, P<0.05 vs VSMC with 3.3 mM P+0.8 mM Mg; <b>b</b>, P<0.05 vs VSMC with 3.3 mM P+1.4 mM Mg. Bars are the mean±SE of three experiments in quadruplicate.</p
Magnesium inhibits β-catenin translocation into the nucleus in VSMC.
<p>VSMC cultured with 3.3+1.4 mM Mg, and 3.3 mM P+1.4 mM Mg+10 µM 2-APB. Control group with 0.9 mM P+0.8 mM Mg was also included. Intracellular localization of β-catenin was visualized by immunofluorescence using confocal microscopy. <b>(A)</b> For each group, β-catenin (green immunofluorescence) is shown left; in the middle the same sample is counterstained with DAPI (blue) for nuclear stain; the merged image is shown right. Images represent four different experiments. <b>(B)</b> Quantification of nuclear β-catenin staining was performed by the Mander's coefficient (M2 plugin: DAPI vs. green). <b>a</b>, P<0.005 vs controls; <b>b</b>, P<0.005 vs VSMC with 3.3 mM P+0.8 mM Mg; and <b>c</b>, P<0.05 vs VSMC with 3.3 mM P+1.4 mM Mg. Bars are the mean±SE of four experiments.</p
Magnesium halts Cbfa-1 expression and up-regulates MGP and OPG when added to VSMC with already existing calcification.
<p>VSMC calcification was induced with 3.3+0.8 mM Mg for 5 days. At the 5<sup>th</sup> day, the medium was switched to 3.3 mM P+1.4 mM Mg, 3.3 mM P+1.4 mM Mg+10 µM 2-APB or 0.9 mM P+0.8 mM Mg and was maintained until day 9. The graphics are the relative mRNA expression of <b>(A)</b> Cbfa-1, <b>(B)</b> osterix, <b>(C)</b> MGP, and <b>(D)</b> OPG. <b>a</b>, P<0.05 vs VSMC with 3.3 mM P+0.8 mM Mg for 5 days 0 days; <b>b</b>, P<0.05 vs VSMC with 3.3 mM P+0.8 mM Mg for 9 days; and c, P<0.01 vs VSMC with 3.3 mM P+1.4 mM Mg for 5 to 9 days. Values are the mean±SE of three experiments in triplicate.</p
Primers used for quantitative RT-PCR analyses.
<p>Primers used for quantitative RT-PCR analyses.</p